Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.40
Ask: 66.00
Change: -1.50 (-2.27%)
Spread: 2.60 (4.101%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cancellation of trading of Yourgene Shares

11 Sep 2023 07:55

RNS Number : 9939L
Novacyt S.A.
11 September 2023
 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

De-listing and cancellation of trading of Yourgene Shares

 

Paris, France and Eastleigh, UK - 11 September 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today's announcement by Yourgene Health plc ("Yourgene"), in relation to the recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the "Acquisition"), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

 

Further to the announcement made by Yourgene on 8 September 2023 that the Scheme has now become Effective in accordance with its terms, Yourgene has today announced that, following an application to the London Stock Exchange, the admission to trading on AIM of Yourgene Shares has been cancelled with effect from 7.00 a.m. today, 11 September 2023.

 

Yourgene's full announcement can be found here: https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/wkjon2r

 

Contacts

 

Novacyt SA

+44 (0)23 8074 8830

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK)

+44 (0)20 7260 1000

Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)

+44 (0)20 3470 0470

 

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780

novacyt@walbrookpr.com

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene's Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFLRADILLIV
Date   Source Headline
12th Jun 20237:00 amRNSReminder to shareholders re. AGM voting
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results
17th Apr 20237:00 amRNSNotice of Results
3rd Apr 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 20234:15 pmRNSLiquidity Agreement and Total Voting Rights
1st Feb 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20237:00 amRNSDHSC Claim update – Trial date listed
26th Jan 20237:00 amRNSFull Year 2022 Trading Update
6th Jan 202312:15 pmRNSHoldings in Company
3rd Jan 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Dec 20227:00 amRNSNon-Executive Director Change
6th Dec 20227:00 amRNSApproval of genesig COVID-19 3G PCR test in UK
1st Dec 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Oct 20226:45 pmRNSCORRECTION: UK CTDA approval of Winterplex 3G
26th Oct 20227:00 amRNSUK Approval of genesig® SARS-CoV-2 Winterplex® 3G
3rd Oct 20223:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20227:00 amRNSHalf year 2022 results
15th Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Sep 202212:00 pmRNSLiquidity Agreement and Total Voting Rights
4th Aug 20227:00 amRNSLaunch of first fully lyophilised PROmate® assays
1st Aug 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jul 20227:00 amRNSLaunch of research-use-only adenovirus F41 assay
20th Jul 20223:00 pmRNSResults of AGM
15th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSApproval of exsig™ COVID-19 Direct test in the UK
7th Jul 20223:00 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSTrading update and progress against strategy
5th Jul 202211:45 amRNSHoldings in Company
1st Jul 202212:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jun 20227:00 amRNSLaunch of monkeypox assay
21st Jun 20222:00 pmRNSNotice of rescheduled AGM
16th Jun 20227:00 amRNSDHSC dispute update
13th Jun 20227:00 amRNSAGM Voting
1st Jun 20221:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Jun 20227:00 amRNSCTDA approval and CE mark
1st Jun 20227:00 amRNSPublication of Annual Report and AGM voting
13th May 20227:00 amRNSNotice of Annual General Meeting
3rd May 202212:21 pmRNSLiquidity Agreement Update and Total Voting Rights
28th Apr 20227:00 amRNSFull year results and update on growth strategy
26th Apr 20227:00 amRNSDHSC dispute update
20th Apr 20227:00 amRNSNotice of Results and Investor Presentation
12th Apr 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
1st Apr 202211:45 amRNSLiquidity Agreement Update and Total Voting Rights
25th Mar 20225:25 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.